Australia is closely awaiting the arrival of retatrutide, a groundbreaking dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, https://susanhwlv404227.wikirecognition.com/2581550/novo_nordisk_s_retatrutide_australia_a_promising_solution_for_obesity_treatment